{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red33\green33\blue33;
\red37\green37\blue37;
\red187\green187\blue187;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red255\green255\blue102;
\red119\green119\blue119;
\red203\green203\blue203;
\red245\green245\blue245;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red80\green80\blue80;
\red51\green51\blue51;
\red56\green124\blue43;
\red151\green151\blue151;
\red181\green79\blue104;
\red21\green137\blue21;
\red0\green114\blue54;
\red106\green144\blue39;
\red247\green247\blue247;
\red254\green254\blue0;
\red232\green233\blue232;
\red61\green61\blue61;
\red227\green227\blue227;
\red240\green240\blue240;
\red105\green105\blue105;
\red255\green248\blue96;
\red233\green233\blue233;
\red249\green249\blue249;
\red112\green112\blue112;
\red204\green255\blue255;
\red229\green243\blue255;
\red179\green218\blue255;
\red255\green255\blue174;
\red255\green255\blue204;
\red255\green204\blue0;
\red188\green41\blue30;
\red190\green237\blue228;
\red190\green190\blue252;
\red102\green102\blue102;
\red86\green86\blue86;
\red250\green250\blue250;
\red70\green70\blue70;
\red218\green218\blue218;
\red250\green222\blue100;
\red61\green61\blue60;
\red255\green128\blue0;
\red239\green122\blue2;
\red255\green194\blue211;
\red236\green236\blue236;
\red153\green153\blue153;
\red71\green120\blue194;
\red240\green248\blue255;
\red127\green127\blue127;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red214\green214\blue214;
\red183\green242\blue206;
\red120\green162\blue47;
\red251\green252\blue255;
\red208\green208\blue208;
\red72\green72\blue72;
\red190\green195\blue204;
\red102\green0\blue102;
\red118\green118\blue118;
\red182\green231\blue243;
\red153\green255\blue102;
\red255\green210\blue183;
\red221\green195\blue236;
\red214\green9\blue9;
\red172\green172\blue172;
\red9\green56\blue84;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 sans-serif;}{
\f4 georgia;}{
\f5 serif;}{
\f6 Source Sans Pro;}{
\f7 Courier New;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid-1917283988\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid822469773}
}
{\*\listoverridetable
{\*\listoverride{\listid822469773\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf21 \f0 \i0 \fs18 
{\b1 \cf21 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Boehringer Ingelheim Pharmaceuticals, Inc. v. HEC Pharm..., Not Reported in Fed....
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_69}{\*\bkmkend co_document_69}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I33c5fa00bea611e6972aa83e6c16e5f7_Target}{\*\bkmkend I33c5fa00bea611e6972aa83e6c16e5f7_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_69}{\*\bkmkend co_readingModeKC_69}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_69}{\*\bkmkend co_readingModeCitatorFlag_69}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I33c5fa00bea611e6972aa83e6c16e5f7&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Red Flag - Severe Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_69}{\*\bkmkend co_readingModeNegativeTreatment_69}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Reversed and Remanded by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/Ia75a2d8067e811eab47fc33bf795b230/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3ForigDocGuid%3DI33c5fa00bea611e6972aa83e6c16e5f7&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=b360031fa5894f02ba28ce2a4616d4d6&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Boehringer Ingelheim Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc.
}
{\b0 \cf23 \f2 \i0 \fs16 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
March 16, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016 WL 7177704
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, D. New Jersey.
\par 
}
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., et al., Plaintiffs,
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf19 \f4 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5035563369)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf23 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
HEC PHARM CO., LTD.
}}}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, et al., Defendants.
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Civil Action No: 15-cv-5982 (PGS)(TJB)
\par 
}
}
}
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Signed 12/07/2016
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f4 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Filed 12/08/2016
\par 
}
}
}
}
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_69}{\*\bkmkend co_attorneysAndLawFirms_69}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0154933501&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Liza M. Walsh
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0358215601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christine Intromasso Gannon
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0488614101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher J. Borchert
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0478179201&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Katelyn O\rquote Reilly
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Walsh Pizzi O\rquote Reilly Falanga LLP, Newark, NJ, for Plaintiffs.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0305863601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Stamatios Stamoulis
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0330671701&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Richard Charles Weinblatt
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Stamoulis & Weinblatt LLC, Wilmington, DE, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0106576601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Arnold B. Calmann
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0381148301&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Geri L. Albin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0334085801&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jeffrey S. Soos
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Saiber LLC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0328855601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Mayra Velez Tarantino
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0125941301&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Michael E. Patunas
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Patunas Tarantino LLC, Newark, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0489290899&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kai Wendell Marshall-Otto
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0482726101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Steven J. Daroci
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0460727001&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Steven James Link
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0215859601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Karen A. Confoy
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Fox Rothschild LLP, PC, Lawrenceville, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0493066999&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jacqueline M. Weyand
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0155795001&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Philip L. Hirschhorn
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Buchanan Ingersoll & Rooney PC, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0469062601&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dan Feng Mei
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0468180001&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Saira Bano Haider
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Axinn Veltrop & Harkrider LLP, New York, NY, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0162709001&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Roy Henry Wepner
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0391085801&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fahd Khalid Majiduddin
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0492152399&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Maegan A. Fuller
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0144207901&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Paul Hilger Kochanski
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0152936701&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
William L. Mentlik
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0144207901&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Paul H. Kochanski
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Lerner, David, Littenberg, Krumholz & Mentlik, LLP, Westfield, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0491910499&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Anthony Sylvester
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0431901701&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Anthony C. Valenziano
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Sherman Wells Sylvester & Stamelman LLP, Florham Park, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0327590701&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Brian T. Moriarty
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hamilton, Brook, Smith & Reynolds, P.C., Boston, MA, Vijayant Pawar, Pawar Gilgallon & Rudy, Morristown, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0352018801&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christina Lynn Saveriano
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0129248001&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eric I. Abraham
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Hill Wallack, LLP, Princeton, NJ, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0338631301&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Salvatore R. Guerriero
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., Philadelphia, PA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0392292401&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
George John Barry, III
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, McGuireWoods LLP, Atlanta, GA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0370262701&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nancy Ann Del Pizzo
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0322311501&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory D. Miller
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Rivkin Radler LLP, Hackensack, NJ, for Defendants.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_69}{\*\bkmkend co_opinion_69}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia49633b2230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia49633b2230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4da8fb1230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4da8fb1230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4da8fb1230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4da8fb1230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb800 
OPINION
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0196120501&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
SHERIDAN
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, U.S.D.J.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_69}{\*\bkmkend co_pp_sp_999_1_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This matter comes before the Court on Defendants\rquote  motion to dismiss (ECF 328) the claims 10-17, 24 and 25 of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Pat. 8,853,156 (hereinafter \u8220\'3fthe \lquote 156 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 identifies 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as an antihyperglycemic agent which improves glucose tolerance in patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 notes that patients who are adversely impacted or intolerable to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 treatment (elderly and diabetic patients) generally experience several adverse symptoms, such as, decreased renal function, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib852a37e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hypoglycemia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, weight gain, edema, bone fracture, gastrointestinal side effects, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iba86e88c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and/or cardiac effects (hereinafter \u8220\'3ftargeted patient population\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 generally concerns with the issue of decreased renal function because of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 largely being excreted through the kidneys, and this issue requires careful monitoring and dosage regulation when treating elderly patients in the targeted patient population. In order to address this issue, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discloses a pharmaceutical drug (DPP-IV inhibitor), which is mainly excreted via the liver and only to a minor extent via the kidney. As such, the monitoring of the targeted patient population is not necessary.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants\rquote  allege that the aforementioned claims are patent ineligible because the claims recite a natural law that is based on pharmacokinetic observations of diabetic patients. As such, Defendants\rquote  move to dismiss the cited claims of infringement because they are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In contrast, Plaintiffs\rquote  argue the motion should be denied because\u8212\'3f(i) claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed towards methods of treating the targeted patient population with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 using non-naturally existing compounds, namely, DPP-IV inhibitors, which alter the natural state of the body in a new and useful way, and hence do not fall within the natural phenomena exception; (ii) there are factual disputes concerning the understanding of a person skilled in the art regarding DPP-IV inhibitors; and (iii) the patent eligibility challenge to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is procedurally barred because Defendants failed to disclose their 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 defense.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
After a careful consideration of the briefs and oral arguments, the Court grants Defendants\rquote  motion to dismiss the claims 10-17, 24 and 25 of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as being directed to patent ineligible subject matter for the reasons set forth below.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4dd9cf1230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4dd9cf1230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa200 \sb400 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul1 \strike0 \i1 \fs20 \sa0 \sb0 
\rquote 156 Patent
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The inventive concepts disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relate to the use of DPP-IV inhibitors for treating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, particularly 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic21f078b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (especially 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), in the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 1, ll. 5-10; col. 9, ll. 30-45). The Court notes that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 includes a total of twenty-five (25) claims, wherein claims 1, 23, 24 and 25 are in independent form.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Conventional antidiabetic or antihyperglycemic agents used for treating blood sugar levels include, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, sulphonylureas, thiazolidinediones, glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, as well as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analogues. However, these conventional antidiabetic agents have various side effects such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a5d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lactic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or gastrointestinal side effects; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib852a37e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
hypoglycemia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or weight gain; edema, bone fracture, weight gain or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iba86e88c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; and gastrointestinal adverse effects. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 1, ll. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
-50).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_69}{\*\bkmkend co_pp_sp_999_2_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 With respect to treatment with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, adverse symptoms include gastrointestinal side effects or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a5d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lactic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which may lead to decreased renal function. As such, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy can be inappropriate for the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 1, ll. 55-67). Accordingly, the inventive concepts disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed towards disclosing a pharmaceutical drug, which is mainly excreted via the liver and only to a minor extent via the kidney. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 3, ll. 10-15; col. 23, ll. 1-10).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further discloses that DPP-IV inhibitors interfere with the plasma level of bioactive peptides, including the peptide GLP-1; and are considered to be promising drugs for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic21f078b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The uses of DPP-IV inhibitors in metabolic (especially diabetic) diseases are disclosed in numerous references as discussed in col. 4, ll. 15-25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The drugs belonging to the DPP-IV inhibitor class include, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Vildagliptin, Saxagliptin and Alogliptin. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discusses the different structural formulations of the aforementioned drugs, the patent(s) and/or publications in which they are disclosed, the specific salts of the aforementioned drugs, and their formulation. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 4, ll. 25\u8212\'3fcol. 9, ll. 30).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further discloses that the DPP-IV inhibitors may be combined with one or more conventional antihyperglycemic agents selected from sulphonylureas, thiazolidinediones (e.g. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c1fc671475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
pioglitazone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analogues, for use in (first line) therapy of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients for the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 12, ll. 27-
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
According to the inventive concepts of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the DPP-IV inhibitor may be an oral DPP-IV inhibitor, whose active metabolites have a wide therapeutic window, and that are eliminated via hepatic metabolism or biliary excretion. The DPP-IV inhibitor of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is substantially or mainly excreted via the liver for which renal excretion represents no substantial or only a minor elimination pathway. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 13, ll. 40-50). The DPP-IV inhibitors disclosed in various embodiments in cols. 15, 16, 17, 18 and 19 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 allegedly improve on the conventional DPP-IV inhibitors by combining exceptional potency and a long-lasting effect with (i) favorable pharmacological properties, (ii) receptor selectivity and (iii) a favorable side effect profile, or bringing about unexpected therapeutic advantages, or improvements when combined with other pharmaceutical active substances. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 19, ll. 30-
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In a preferred embodiment (embodiment A), the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discloses that DPP-IV inhibitors can be prepared using synthetic methods as described in the literature. The purine derivatives of formula (I) can be obtained as described in various disclosures. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 19, ll. 50-65). As such, the pharmaceutical compositions, according to the invention disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 comprising the DPP-IV inhibitors, are prepared by the skilled person using pharmaceutically acceptable formulation excipients as described in the art. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 20, ll. 30-
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to administering the DPP-IV inhibitors to a patient, according to preferred embodiment A of the DPP-IV inhibitors, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discloses that the dosage typically required of the DPP-IV inhibitors, when administered intravenously, is 0.1 mg (milligram) to 10 mg, preferably 0.25 mg to 5 mg, for a duration of one (1) to four (4) times a day. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 21, ll. 20-25).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_69}{\*\bkmkend co_pp_sp_999_3_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 A preferred example of DPP-IV inhibitor disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is the BI 1356 inhibitor.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012040501436_ID0ESKAE_69}{\*\bkmkend co_fnRef_B00012040501436_ID0ESKAE_69}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012040501436_69" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The BI 1356 \u8220\'3fexhibits high potency, 24 h [hour] duration of action, and a wide therapeutic window.\u8221\'3f According to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 receiving multiple oral doses of 1, 2.5, 5 or 10 mg of BI 1356, once daily for twelve (12) days, show favorable pharmacodynamics and pharmacokinetic profile (shown in Table 1, col. 23, ll. 15-
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) with rapid attainment of steady state. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 22, ll. 40-50). BI 1356 is mainly excreted via the liver and only to a minor extent via the kidney. The fraction of BI 1356 eliminated via the kidneys increases very slightly over time. The non-renal elimination of BI 1356 in combination with its low accumulation potential and broad safety margin may be of significant benefit to the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 23, ll. 1-10).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further discloses that the drugs belonging to the DPP-IV inhibitor class (i.e., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Vildagliptin, Saxagliptin and Alogliptin) may be used in conjunction with other active substances such that improved treatment results can be obtained. The active substances which may be obtained commercially as pharmaceutical compositions are described in numerous places in the prior art, for example, the \u8220\'3fRote Liste\u174\'3f\u8221\'3f of the federal association of pharmaceutical industry, or in the annual \u8220\'3fPhysicians\rquote  Desk Reference.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 23, ll. 60\u8212\'3fcol. 24, ll. 2). The particular antidiabetic partner drugs, especially for patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, for the combined use with the DPP-IV inhibitors may include, for example, glibenclamide, dlimepiride and gliquidon. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 25, ll. 45-50).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4e51701230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4e51701230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa200 \sb400 
Declaration of Dr. Utpal Pajvani
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dr. Pajvani, on behalf of Plaintiffs, provides a declaration in support of Plaintiffs\rquote  memorandum of law in opposition to Defendants\rquote  
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion to dismiss the claims 10-17, 24 and 25 of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Dr. Utpal Pajvani\rquote s Declaration (\u8220\'3fPajvani Decl.\u8221\'3f), ECF 354-1).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dr. Pajvani recognizes that claims 10-17, which are asserted by Plaintiffs against Defendants, depend from independent claim 1, and as such claims 10-17 include all the limitations set forth in claim 1. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 15). In paragraphs 19 and 20 of Dr. Pajvani\rquote s declaration, Dr. Pajvani indicates that DPP-IV enzymes are the key players in a glycogenesis process (i.e., when the blood glucose level is high). That is, DPP-IV enzymes, which are found on the surface of the cells, rapidly inactivates or degrades the hormones\u8212\'3fGLP-1 (glucagon-like peptide) and GIP (glucose-dependent insulotropic polypeptide)\u8212\'3fwhich are responsible for the release of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and as such depress the level of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in the body. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 21).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to the inventive concepts recited in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, in particular claims 10-17 and 24-25, Dr. Pajvani indicates that the aforementioned natural process is artificially modified in order to treat and/or prevent 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In particular, Dr. Pajvani notes that the DPP-IV inhibitors, which are synthetic compounds, bind to the DPP-IV enzymes that are on the surface of the cells in order to inactivate the DPP-IV enzymes. The DPP-IV enzymes are inhibited due to their inactivation. By inhibiting the DPP-IV enzymes, the half-life of GLP-1 and GIP hormones is artificially lengthened. The increased levels of GLP-1 and GIP hormones causes the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I3707743e475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
pancreases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to increase 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 secretion and decrease 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c201477475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glucagon
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 secretion, which in turn leads to decreased level of glucose in the blood. Accordingly, these series of reactions result in lowering blood glucose level in the body. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 22).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_69}{\*\bkmkend co_pp_sp_999_4_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Unlike the DPP-IV inhibitors of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the DPP-IV inhibitors prior to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, saxagliptin, vildagliptin, and alogliptin, require dose adjustment for the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 32). As such, like 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the aforementioned four DPP-IV inhibitors, require regular 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib0dd4e14475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
monitoring of kidney function
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which is labor-intensive for the treating physician and often leads to a decreased adherence of regular monitoring of the targeted patient population. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 33, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Exhibit F. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=bdrug&entityId=I2c3429d84f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Januvia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Prescribing Information at 2; Exhibit G, Onglyza Prescribing Information at 2; Ex. H, Galvus Prescribing Information, 19; Exhibit I, Nesina Prescribing Information, at 2). Dr. Pajvani indicates that the since regular 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib0dd4e14475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
monitoring of the kidney functions
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the targeted patient population, who are taking 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, saxagliptin, vildagliptin, and alogliptin, are at the very early stages of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, it is of particular importance because the targeted patient population will not have their medication dosage adequately adjusted, which may result in dangerous side effects. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 33).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
According to Dr. Pajvani, unlike the conventional DPP-IV inhibitors, the inventive concepts disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not require dose adjustment in patients with any degree of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Declaration of Dr. Pajvani in support of Plaintiffs\rquote  Opening Claim Construction Brief, ECF 349 at \u182\'3f 16).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court recognizes the distinction of no dose adjustments required for the pharmaceutical drug disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; however, the Court notes that the cited claims of infringement of the
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent do not claim dose adjustments to treat the targeted patient population. Instead, the cited claims of infringement further define the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the specific contraindication experienced by the targeted patient population, and the processing of the DPP-IV inhibitors by the human body upon ingestion of the same. As such, the inventive concepts of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 not requiring dose adjustment is not an issue in the cited claims of infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4e935b1230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4e935b1230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf23 \f2 \i0 \fs20 
{\b1 \cf23 \f2 \i1 \fs20 
{\b1 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(c)
}
}
}}}
\sa200 
\sb400 
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c) of the Federal Rules of Civil Procedure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 permits a party to dismiss a suit \u8220\'3f[a]fter the pleadings are closed ... but early enough not to delay trial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For a complaint to survive dismissal, it \u8220\'3fmust contain sufficient factual matter, accepted as true, to \u8216\'3fstate a claim to relief that is plausible on its face.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036091998&pubNum=0007903&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wireless Media Innovations, LLC v. Maher Terminals, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 100 F.Supp.3d 405 (D.N.J. April 20, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2018848474&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_678&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_678" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ashcroft v. Iqbal
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 556 U.S. 662, 678 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). In determining the sufficiency of a complaint, the Court must accept all well-pleaded factual allegations in the complaint as true and draw all reasonable inferences in favor of the nonmoving party. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015125207&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_234&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_234" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Phillips v. County of Allegheny
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 515 F.3d 224, 234 (3d Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb600 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A motion for judgment on the pleadings is \u8220\'3ffunctionally identical\u8221\'3f to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(b)(6)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 motion to dismiss for failure to state a claim. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038151490&pubNum=0000999&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cave Consulting Group, Inc. v. Truven Health Analytics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 283478, at *1 (N.D. Cal. Jan. 25, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1989014572&pubNum=0000350&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_350_1192&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1192" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Dworkin v. Hustler Magazine, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 867 F.2d 1188, 1192 (9th Cir. 1989)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); (
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036471005&pubNum=0000999&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Affinity Labs of Texas, LLC v. Amazon.Com, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2015 WL 3757497 (W.D. Tx. June 12, 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2016114752&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_418&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_418" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Doe v. MySpace, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 528 F.3d 413, 418 (5th Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The Court must accept \u8220\'3fall factual allegations in the complaint as true and construe them in light most favorable to the non-moving party.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4eba6b1230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4eba6b1230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
(I)
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order to consider Defendants\rquote  motion to dismiss the claims of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (ECF 328), the Court must first determine whether claim construction is necessary.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In recent years, precedent holds that courts may properly decide the question of patent eligibility at the pleading stage and without first construing the claim terms. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036091998&pubNum=0007903&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_7903_410&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_410" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Wireless Media
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 100 F.Supp.3d at 410
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028287013&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1273&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1273" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bancorp Servs., L.L.C. v. Sun Life Assur. Co. of Canada (U.S.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), 687 F.3d 1266, 1273 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[C]laim construction is not an inviolable prerequisite to a validity determination under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f)) Where appropriate, district courts have adjudicated subject matter eligibility before claim construction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Courts have indeed dismissed patent suits on the pleadings because the patents were ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032127086&pubNum=0004637&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_4637_205&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_4637_205" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Lumen View Tech. LLC v. Findthebest.com, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 984 F.Supp.2d 189, 205 (S.D.N.Y. 2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (granting judgment on the pleadings because \u8220\'3f[t]he claimed process elements of Claim 1 are straightforward.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_69}{\*\bkmkend co_pp_sp_999_5_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 A motion challenging validity of a patent under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 may be brought at the motion to dismiss stage. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039511143&pubNum=0000999&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eagle View Technologies, Inc. v. Xactware Solutions, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2016 WL 4154136 (D.N.J. Aug. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_717&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_717" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial, Inc. v. Hulu, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 772 F.3d 709, 717 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming district court\rquote s invalidity ruling on a motion to dismiss)). \u8220\'3fAlthough the determination of patent eligibility requires a full understanding of the basic character of the claimed subject matter, claim construction is not an inviolable perquisite to a validity determination under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035137097&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1349&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1349" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Content Extraction & Transmission LLC v. Wells Fargo Bank, Nat\rquote l Ass\rquote n
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 776 F.3d 1343, 1349 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). But, \u8220\'3fit will ordinarily be desirable\u8212\'3fand often necessary\u8212\'3fto resolve claim construction disputes prior to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2028287013&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1273&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1273" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bancorp Servs., L.L.C. v. Sun Life Ass. Co. of Can. (U.S.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
), 687 F.3d 1266, 1273 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although claim construction of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 has not been conducted, there has been sufficient briefing that the Court \u8220\'3f[understands] the basic character of the claimed subject matter,\u8221\'3f to determine Defendants\rquote  motion to dismiss the claims of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 on the pleadings. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eagle View
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=0000999&cite=2016WESTLAW415413&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=DE&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016 WL 415413, at *2
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAlthough the determination of patent eligibility requires a full understanding of the basic character of the claimed subject matter, claim construction is not an inviolable perquisite to a validity determination under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f) (internal citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia4ef0211230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia4ef0211230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
(II)(A)
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For purposes of determining patent eligibility of the claims of infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court limits its review and analysis to claims 10-17 and 24-25 because only these aforementioned claims have been asserted for infringement against Defendants. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defs.\rquote  Br. at 3, fn. 4, ECF 331). Since Boehringer narrowed its asserted claims after the pleadings were closed, we are limiting our decision only to these claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The statute, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, provides that patents may only issue for \u8220\'3fany new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof.\u8221\'3f However, the Supreme Court \u8220\'3fha[s] long held that this provision contains an important implicit exceptions: Laws of nature, natural phenomena, and abstract ideas [which] are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\rquote l
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. 2347, 2354 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2116&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2116" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 133 S.Ct. 2107, 2116 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (internal quotations omitted). As explained by the Supreme Court, \u8220\'3fthe concern that drives this exclusionary principle [is] one of pre-emption.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). \u8220\'3fThe ultimate question of patent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is an issue of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2035063513&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_759&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_759" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re BRCA1\u8212\'3fand BRCA2\u8212\'3fBased Hereditary Cancer Test Patent Litig.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 774 F.3d 755, 759 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In evaluating whether a patent claim recites patent eligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court undertakes a two-step inquiry to determine: (1) whether the claims at issue are directed to a patent ineligible concept (i.e., law of nature, natural phenomena, or abstract idea); and (2) if so, then the Court must determine whether the \u8220\'3fclaim\rquote s elements, considered both individually and \u8216\'3fas an ordered combination,\u8217\'3f \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. 1289, 1297\u8211\'3f98 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Step two of this analysis is a search for an \u8220\'3finventive concept.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_69}{\*\bkmkend co_pp_sp_999_6_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The abstract-idea exception precludes patents that \u8220\'3fwould pre-empt use of [a particular] approach in all fields, and would effectively grant a monopoly over an abstract idea.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022394590&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_3231&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_3231" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bilski v. Kappos
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 130 S.Ct. 3218, 3231 (2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For example, \u8220\'3f[a] mathematical formula as such is not accorded the protection of our patent laws, and this principle cannot be circumvented by attempting to limit the use of the formula to a particular technological environment.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_184&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_184" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 184 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted). \u8220\'3f[M]ethods which can be performed mentally, or which are the equivalent of human mental work, are unpatentable abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025880702&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CyberSource Corp. v. Retail Decisions, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 654 F.3d 1366, 1371 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to what constitutes an \u8220\'3fabstract idea,\u8221\'3f the Court in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 noted that the \u8220\'3fabstract ideas\u8221\'3f category is one that embodies the \u8220\'3flongstanding rule that \u8216\'3f[a]n idea of itself is not patentable.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2355 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1852194692&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_175&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_175" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Le Roy v. Tatham
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 14 How. 156, 175 (1852)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fA principle, in the abstract, is a fundamental truth; an original cause; a motive; these cannot be patented, as no one can claim in either of them an exclusive right\u8221\'3f)). However, the Court also indicated that it need not \u8220\'3flabor to delimit the precise contours of the \u8216\'3fabstract ideas\u8217\'3f category in this case.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 2357; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
also see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1334
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In contrast, \u8220\'3fan application of a law of nature or mathematical formula to a known structure or process may well be deserving of patent protection.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_187&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_187" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 187
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The law of nature or natural phenomena exception precludes patents directed towards phenomena of nature, mental processes, and abstract intellectual concepts, as they are \u8220\'3fbasic tools of scientific and technological work.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_67&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_67" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gottschalk v. Benson
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 409 U.S. 63, 67 (1972)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For example, \u8220\'3fsets of steps conducted entirely by nature are not subject to patenting since they are not invented by man; sets of steps occurring only in the mind are not subject to patenting because mental processes are but disembodied thoughts, whereas inventions which Congress is constitutionally empowered to make patentable are tangible embodiments of ideas in useful or technological arts.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978121343&pubNum=0000350&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_350_1333&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1333" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sarkar
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 588 F.2d 1330, 1333 (CCPA 1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fThe discovery of a law of nature cannot form [the] basis of [a] patent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Armour Pharmaceutical Co. v. Richardson-Merrell, Inc.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 396 F.2d 72 (3d Cir. 1968).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Instead, the \u8220\'3f[p]atented process that focuses upon use of natural law must also contain other elements or combination of elements, sometimes referred to as \u8216\'3finventive concept,\u8217\'3f sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. 1289, 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. An application of a law of nature or mathematical formula to a known structure or process may well be deserving of patent protection. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_187&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_187" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 187-188
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court precedents on the issue of what constitutes patent eligibility have stated that patent claims directed to an abstract idea, a law of nature, or a natural phenomenon are patent ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For example, in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Benson
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court held that an algorithm, or mathematical formula, is like a law of nature, which cannot be the subject of a patent (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1972137547&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Benson
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 409 U.S. 63 at 71
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); and in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Parker v. Flook
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court held that processes using mathematical formulas that, like laws of nature, are not themselves patentable (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see Parker
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978139495&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_590&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_590" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
437 U.S. 584, 590-591 (1978)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Thereafter, about thirty-years later, in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bilski
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court found that the claimed invention that explained how buyers and sellers of commodities in the energy market could protect, or hedge, against the risk of price changes and that reduced this concept of hedging to a mathematical formula was an abstract idea, and thus was not a patentable process (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2022394590&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_3229&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_3229" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bilski
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 130 S.Ct. at 3229
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); and in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court held that \u8220\'3f[the] [p]henomena of nature, though just discovered, mental processes, and abstract intellectual concepts are not patentable, as they are the basic tools of scientific and technological work\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1293
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Lastly, more recently, the Supreme Court in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 held that \u8220\'3fclaims in patents for mitigating settlement risk in financial transactions by using a computer system as a third-party intermediary were directed to a patent-ineligible concept\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. 2347, 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_69}{\*\bkmkend co_pp_sp_999_7_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Supreme Court has also indicated that patent claims directed to an abstract idea, a law of nature, or a natural phenomenon, can be found to be patent eligible if the claims recite additional claim limitations or features that add \u8220\'3fsignificantly more\u8221\'3f to the alleged abstract idea, law of nature, or natural phenomenon such that the claim is transformed into a patent eligible subject matter. For example, in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the Supreme Court held that the overall process was patent eligible because of the way the additional steps of the process integrated the equation into the process as a whole (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_187&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_187" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175 at 187
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); and in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Court held that a human-made bacterium with markedly different characteristics from any found in nature, and one having the potential for significant utility, was considered patentable subject matter, and not nature\rquote s handiwork (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_310&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_310" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 310 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The first prong of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 two step inquiry for determining patent ineligibility was further clarified by the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 stated that the \u8220\'3fdirected to\u8221\'3f inquiry \u8220\'3fapplies a stage-one filter to claims, considered in light of the specification, based on whether \u8216\'3ftheir character as a whole is directed to excluded subject matter.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d at 1335
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036525254&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1346&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1346" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Internet Patents Corp. v. Active Network, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 790 F.3d 1343, 1346 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
also see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1375&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1375" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1375, 2016 WL 1393573, at *5 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (inquiring into \u8220\'3fthe focus of the claimed advance over the prior art\u8221\'3f)). As such, the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 indicated that the first prong of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 two-step inquiry requires determining whether the focus of the claims, in light of the specification, is on a specific asserted \u8216\'3fimprovement\u8217\'3f in that particular technological area. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1335
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022040501436_ID0ETHBG_69}{\*\bkmkend co_fnRef_B00022040501436_ID0ETHBG_69}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022040501436_69" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cautioned that when determining whether claims are directed to patent eligible subject matter, they should not be \u8220\'3fdescribed at a \u8216\'3fhigh level\u8217\'3f of abstraction and untethered from the language of the claims because doing so ensures that exceptions to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 will swallow the rule.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1337 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2354&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2354" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2354
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Court noted that \u8220\'3fwe tread carefully in construing this exclusionary principle [of laws of nature, natural phenomena, and abstract ideas] lest it swallow all of patent law.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Likewise, the Supreme Court also cautioned that over generalizing claims, \u8220\'3fif carried to its extreme, make[s] all inventions unpatentable because all inventions can be reduced to underlying principles of nature which, once known, make their implementation obvious.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_780_189&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_189" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diehr
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. at 189, n. 12
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, we begin with step one\u8212\'3fdetermining whether claims 10-17 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are \u8220\'3fdirected to\u8221\'3f a patent ineligible concept. First, the Court considers independent claim 1 because claims 10-17 depend from claim 1. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Manual of Patent Examining Procedure (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=1015320&cite=MPEPs608.01(n)&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=TS&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
MPEP\u8221\'3f) \u167\'3f 608.01(n)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 112 (d)
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032040501436_ID0E4OBG_69}{\*\bkmkend co_fnRef_B00032040501436_ID0E4OBG_69}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032040501436_69" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Claims 10-17 are in dependent form because they relate back to claim 1, as noted from their respective preamble. Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recites:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method of treating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to at least one contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_69}{\*\bkmkend co_pp_sp_999_8_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 orally administering to the patient a DPP-IV inhibitor wherein the contraindication is selected from the group consisting of: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or renal dysfunction, unstable or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib3ef21e5475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
acute congestive heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, acute or chronic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibf4385e8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and hereditary 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib81069fe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
galactose intolerance
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(col. 29, ll. 2-12 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Claim 1 is a method claim, with a preamble that recites, \u8220\'3ftreating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to at least one contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f The preamble is followed by the transitional phrase of \u8220\'3fcomprising.\u8221\'3f
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042040501436_ID0EMTBG_69}{\*\bkmkend co_fnRef_B00042040501436_ID0EMTBG_69}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042040501436_69" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The transitional phrase is followed by the body of the claim, which includes\u8212\'3f(i) the step of \u8220\'3forally administering to the patient a DPP-IV inhibitor;\u8221\'3f and (ii) a Markush group
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052040501436_ID0E5TBG_69}{\*\bkmkend co_fnRef_B00052040501436_ID0E5TBG_69}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052040501436_69" }{\fldrslt 
{\super \b0 \cf23 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 following a wherein clause that further defines the different types of contraindications associated with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy. The end result is to treat a targeted patient population with a DPP-IV inhibitor.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Defendants\rquote  assert in their briefs that the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent ineligible because they recite a natural law that are essentially directed to pharmacokinetic observations of diabetic patients. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defs.\rquote  Br. at 5-14, ECF 331). In contrast, Plaintiffs\rquote  assert that the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent eligible because they recite methods of using non-naturally existing compounds, namely DPP-IV inhibitors, which alter the natural state of the body in a new and useful way. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pls.\rquote  Br. at 11-17, ECF 354). In support of their position, Plaintiffs\rquote  rely on the recent Federal Circuit case, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042 (Fed. Cir. July 5, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court does not find Plaintiffs\rquote  arguments persuasive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit found the claims at issue to be directed to \u8220\'3fa new and useful laboratory technique for preserving hepatocytes.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court noted that unlike the claims in recent cases that amounted to nothing more than observing or identifying the ineligible concept itself, the claims in the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were immediately distinguishable. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations omitted). That is, the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recited detailed steps in the claims that achieved a better way of preserving the hepatocytes. In particular, the Court noted that \u8220\'3f[b]ecause the claimed process involves both multiple freeze-thaw cycles and pooling cells from various donors, it results in a preparation that is both new and vastly more useful for research than hepatocyte preparations made by conventional methods.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048-49
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In other words, the claims at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 required a series of steps such as\u8212\'3f(i) subjecting hepatocytes that have frozen and thawed to separate viable hepatocytes from nonviable hepatocytes; (ii) recovering separated viable hepatocytes; (iii) cryopreserving the recovered viable hepatocytes to thereby form said desired preparation of hepatocytes; and (iv) resulting in a new and improved hepatocyte that was not disclosed in the conventional methods. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1046&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1046" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1046
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_9_69}{\*\bkmkend co_pp_sp_999_9_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*9
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 However, the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are not similar to the claims in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. For example, claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 only recites a single instruction of \u8220\'3forally administering\u8221\'3f a DPP-IV inhibitor to the targeted patient population rather than a series of steps tied to tangible embodiments. In brief, claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides no contribution over conventional knowledge of administering DPP-IV inhibitors.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The case of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is more analogous to the claims at issue here. In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court found that \u8220\'3f[c]laim 1 [...] states that 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
if
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the levels of 6\u8211\'3fTG in the blood (of a patient who has taken a dose of a thiopurine drug) exceed about 400 pmol per 8x10
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 red blood cells, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
then
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the administered dose is likely to produce toxic side effects. While it takes a human action (the administration of a thiopurine drug) to trigger a manifestation of this relation in a particular person, the relation itself exists [...] apart from any human action.\u8221\'3f In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court noted that the relation between the blood levels and the thiopurine drug was a consequence of the ways where thiopurine compounds were metabolized by the body, which the Court determined to constitute \u8220\'3fentirely natural processes.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1296-97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, here, claim 1 recites to, orally administer a DPP-IV inhibitor. Upon administering the DPP-IV inhibitor, the natural biological process in the human body operates to increase the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c670878475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
insulin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 secretion. Thereby, decreasing the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3c201477475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
glucagon
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 secretion and reducing the level of glucose in the blood. Subsequent thereto DPP-IV inhibitor is substantially or mainly excreted via the liver and only to a minor extent via the kidney (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 22; the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 13, ll. 40-50; col. 23, ll. 1-10).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court recognizes that Defendants\rquote  in their briefs, in reliance on 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, advance the position that the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are patent ineligible because they are directed to a natural law. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defs.\rquote  Br. at 5-14, ECF 331). However, the Court notes that unlike the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which required administering a dose upon determining that certain levels in the blood were increased; claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, at its core, simply recites the act of \u8216\'3fadministering\u8217\'3f a DPP-IV inhibitor because it does not require any prior determination that natural body levels have changed or altered before performing the step of administering the DPP-IV inhibitor. As such, the act of administering the DPP-IV inhibitor to the targeted patient population, as noted in claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, is an abstract idea. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025880702&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CyberSource Corp. v. Retail Decisions, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 654 F.3d 1366, 1371 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[M]ethods which can be performed mentally, or which are the equivalent of human mental work, are unpatentable abstract ideas....\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1293&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1293" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1293
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fPhenomena of nature, though just discovered, mental processes, and abstract intellectual concepts are not patentable, as they are the basic tools of scientific and technological work.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Additionally, pursuant to Federal Circuit\rquote s guidance in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with respect to determining whether the focus of the claims, in light of the specification, is on a specific asserted \u8216\'3fimprovement\u8217\'3f in that particular technological area when determining what the claims are \u8220\'3fdirected to,\u8221\'3f the Court finds claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to be directed to an abstract idea. Here, the improvement over the conventional DPP-IV inhibitors is that the DPP-IV inhibitors disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are mainly excreted via the liver, and only to a minor extent via the kidney, in order to treat the targeted patient population. As such, the monitoring of the targeted patient population is not necessary. However, the improvement of having the DPP-IV inhibitors excreted via the liver, instead of the kidney, is performed at the anatomical level of the human body, where a series of reactions in the human body process the DPP-IV inhibitor under the natural biological process. Accordingly, the Court finds that claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which recites a single instruction of administering the DPP-IV inhibitor to the targeted patient population, is directed to an abstract idea.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia5032651230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia5032651230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
(II)(B)
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_10_69}{\*\bkmkend co_pp_sp_999_10_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*10
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Now the Court turns to the second step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 framework to search for an \u8220\'3finventive concept.\u8221\'3f That is, the Court now determines whether the \u8220\'3fclaim\rquote s elements, considered both individually and \u8216\'3fas an ordered combination,\u8217\'3f \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
also see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (The requirement for substantive claim limitations beyond the mere recitation of a disembodied fundamental concept has \u8220\'3fsometimes\u8221\'3f been referred to as an \u8220\'3finventive concept\u8221\'3f) (internal citations omitted). The \u8220\'3finventive concept\u8221\'3f equates to an element or a combination of elements, recited in the claim, which are \u8220\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit noted that the claim limitations must be examined to determine whether the claims contain an \u8220\'3finventive concept\u8221\'3f to \u8220\'3ftransform\u8221\'3f the claimed abstract idea into a patent eligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034793628&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_715&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_715" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ultramercial
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 772 F.3d at 715
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2357" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2357
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The transformation of an abstract idea into a patent eligible subject matter \u8220\'3frequires more than simply stat[ing] the [abstract idea] while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3fA claim that recites an abstract idea must include \u8216\'3fadditional features\u8217\'3f to ensure \u8216\'3fthat the [claim] is more than a drafting effort designed to monopolize the [abstract idea].\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1297&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1297" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1297
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Those \u8220\'3fadditional features\u8221\'3f must be more than the \u8220\'3fwell-understood, routine, conventional activity.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
When analyzing the \u8220\'3fadditional features\u8221\'3f as being more than well-understood, routine and conventional activity, the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bascom
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cautioned that such determination should not undertake an obviousness analysis under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039262742&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1350&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1350" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bacsom Global Internet v. AT&T Mobility, LLC
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1341, 1350 (Fed. Cir. June 27, 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe district court\rquote s analysis in this case, however, looks similar to an obviousness analysis under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, except lacking an explanation of a reason to combine the limitations as claimed. The inventive concept inquiry requires more than recognizing that each claim element, by itself, was known in the art. As is the case here, an inventive concept can be found in the non-conventional and non-generic arrangement of known, conventional pieces.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, when considering claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as a whole, the Court finds that the additional features recited in claim 1 do not amount to \u8220\'3fsignificantly more,\u8221\'3f which transform the abstract idea of administering the DPP-IV inhibitor to a patent eligible subject matter. That is, when considering the following additional features\u8212\'3f(i) the preamble of claim 1, \u8220\'3ftreating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to at least one contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
;\u8221\'3f and (ii) the body of claim 1, \u8220\'3fwherein the contraindication is selected from the group consisting of: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or renal dysfunction, unstable or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib3ef21e5475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
acute congestive heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, acute or chronic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibf4385e8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and hereditary 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib81069fe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
galactose intolerance
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f\u8212\'3fin conjunction with \u8220\'3forally administering to the patient a DPP-IV inhibitor,\u8221\'3f as recited in claim 1, the Court finds that these additional features recite well-understood, routine, and conventional activity that do not transform the abstract idea into an \u8216\'3finventive concept.\u8217\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For example, with respect to the preamble and the wherein clause recited in the body of claim 1, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 discloses, \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a common disease of increasing prevalence worldwide and may be associated with [...] microvascular complications such as [...] and/or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib89aa8ef475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
;\u8221\'3f \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 can be associated with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a5d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
lactic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or gastrointestinal side effects [...] [and] thiazolidinediones can be associated with edema, bone fracture, weight gain or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iba86e88c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
/cardiac effects.\u8221\'3f (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 1, ll. 20-25, 40-45). These disclosures indicate that the inventor of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recognized that these aforementioned issues were known and well-understood in the scientific community. That is, it was known and well-understood in the medical community that the targeted patient population may experience 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2ccd43d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
congestive heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and/or hereditary 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib81069fe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
galactose intolerance
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 12, ll. 27-
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
also see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 15).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_11_69}{\*\bkmkend co_pp_sp_999_11_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*11
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court notes that unlike the claims in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not amount to significantly more than an abstract idea of providing an instruction for a medical care professional who is treating the targeted patient population. The instruction of claim 1 can be conducted via mental processes, which is not tied to any tangible embodiments. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1978121343&pubNum=0000350&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_350_1333&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1333" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sarkar
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 588 F.2d at 1333
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fsets of steps occurring only in the mind are not subject to patenting because mental processes are but disembodied thoughts\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_2357&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2357" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S.Ct. at 2357
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
citing
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1298&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1298" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1298
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fthe process at issue amounted to \u8216\'3fnothing significantly more than an instruction to doctors to apply the applicable laws when treating their patients.\u8217\'3f \u8221\'3f)).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The only improvement over the conventional DPP-IV inhibitors (i.e., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Vildagliptin, Saxagliptin and Alogliptin) (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 22, ll. 1-25; col. 23, ll. 60\u8212\'3fcol. 24, ll. 2) being that the DPP-IV inhibitor disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 would not require dose adjustments in patients with any degree of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the DPP-IV inhibitors are mainly excreted via the liver, and only to a minor extent via the kidney. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 23, ll. 1-10; Pajvani Decl. \u182\'3f 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Declaration of Dr. Pajvani in support of Plaintiffs\rquote  Opening Claim Construction Brief, ECF 349 at \u182\'3f 16). However, the Court finds that the aforementioned additional features of claim 1, singly and in an ordered combination, recite a well-understood, routine, conventional activity, as recognized by the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which do not transform the abstract idea of administering DPP-IV inhibitor to a patent eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, the Court finds that claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is patent ineligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because claim 1 is directed to an abstract idea of administering a drug to a targeted patient population, and the additional claim limitations recited in claim 1 do not add \u8220\'3fsignificantly more\u8221\'3f to the aforementioned abstract idea in order to transform claim 1 into a patent eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia50a5241230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia50a5241230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa200 \sb400 
Claims 10-17 and 24-25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul1 \strike0 \i1 \fs20 \sa0 \sb0 
\rquote 156 Patent
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Now, the Court focuses on claims 10-17 and 24-25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which Plaintiffs\rquote  assert against Defendants for infringement. As noted above, claims 10-17 are dependent claims that depend from independent claim 1. As a dependent claim, all the limitations of the claim to which it refers (i.e., claim 1) are incorporated by reference in the dependent claim. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 112(d)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
supra
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 fn. 3). As such, for claims 10-17, which depend from claim 1, all the limitations of claim 1 are incorporated into claims 10-17, respectively. That is, claim 10, for example, recites,
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method of treating and/or preventing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate due to at least one contraindication against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
orally administering to the patient a DPP-IV inhibitor wherein the contraindication is selected from the group consisting of: 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or renal dysfunction, unstable or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib3ef21e5475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
acute congestive heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, acute or chronic 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibf4385e8475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic acidosis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, and hereditary 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ib81069fe475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
galactose intolerance
}}}
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and wherein the contraindication is 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 or renal dysfunction, and wherein said DPP-4 inhibitor is used for said patient in the same dose as for a patient with normal renal function.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 29, ll. 2-12; col. 31, ll. 55-60 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The Court notes that the additional features added by claim 10 to claim 1 are limiting or further defining\u8212\'3f(i) the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recited in claim 1 to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (ii) the contraindication recited in claim 1 to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or renal dysfunction; and (iii) the dose of DPP-4 inhibitor for patients with normal renal functions. The Court notes that the \u8220\'3fDPP-4 inhibitor\u8221\'3f recited in claim 10 refers to the \u8220\'3fDPP-IV inhibitor\u8221\'3f recited in claim 1. The only difference being the Roman numeral annotation in claim 1.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_12_69}{\*\bkmkend co_pp_sp_999_12_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*12
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court finds that these additional features recited in claim 10 are well-understood, routine, and conventional features that do not transform the abstract idea recited in claim 1 into a patent eligible subject matter. For example, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recognizes that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a common disease associated with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and/or failure, and that remains inadequately treated, partly because of limitations in long term efficacy, tolerability and dosing inconvenience of existing antihyperglycemic therapies. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, col. 1, ll. 15-30). The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 also discloses that drugs belonging to the DPP-IV inhibitor class include, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sitagliptin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Vildagliptin, Saxagliptin and Alogliptin, and how their structural formulations can be modified in order to achieve a desired result for treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic diseases
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 4, ll. 25\u8212\'3fcol. 9, ll. 30). As such, the Court notes that these additional features recite additional instructions that are well-understood, routine and conventional features in the art, as noted by the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and that do not tie the abstract idea of claim 1 of \u8216\'3fadministering\u8217\'3f a drug to any tangible embodiments. Accordingly, the Court finds that the additional features recited in claim 10 do not transform the abstract idea recited in claim 1 into a patent eligible subject matter.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
With respect to claims 11-17, the following additional features are added to claim 1 \u8212\'3f(i) the DPP-4 inhibitor and its major active metabolite(s) are primarily eliminated via hepatic metabolism or biliary excretion (claim 11); (ii) the DPP-4 inhibitor is excreted mainly via the liver (claim 12); (iii) excretion via the kidney represents a minor elimination pathway (claim 13); (iv) the DPP-4 inhibitor is excreted mainly unchanged (claim 14); (v) elimination via metabolism represents a minor elimination pathway (claim 15); (vi) the DPP-4 inhibitor has placebo-like safety/tolerability and/or is eliminated primarily as the parent drug via the liver (claim 16); and (vii) the main metabolite of the DPP-4 inhibitor is pharmacologically inactive (claim 17).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court finds that the additional features recited in claims 11-17 do not add \u8220\'3fsignificantly more\u8221\'3f to the abstract idea of claim 1. Instead, some of these additional features recite a natural phenomenon. For example, DPP-IV inhibitor being eliminated via hepatic metabolism, biliary excretion, or the liver; excretion via the kidney represents a minor elimination pathway, etc., represent a natural phenomenon of how the human body is interacting with the DPP-IV inhibitor that has been orally administered to a targeted patient population. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_708_1296&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1296" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S.Ct. at 1296-97
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
also see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Pajvani Decl. \u182\'3f 22 (DPP-IV inhibitors, use of which is recited in claim 10-17 and 24-25, which are synthetic compounds, inhibit DPP-IV enzymes on the surface of the cells. This, in effect results in series of reactions in the human body to lower the blood glucose level in the body).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, the Court finds that the additional features recited in claims 11-17 do not add \u8220\'3fsignificantly more\u8221\'3f to the abstract idea of claim 1. As such, claims 11-17 do not render claim 1 patent eligible under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lastly, with respect to claims 24 and 25, the Court notes that these are additional independent claims, distinct from claim 1, as they do not relate back to another claim in their preamble. Claims 24 and 25, like claim 1, are method claims \u8220\'3fof treating [type] 2 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic21f078b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetes mellitus
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate\u8221\'3f. Upon review of claims 24 and 25, the Court notes that the aforementioned claims are similar to claim 1 in multiple respects. For example, claims 24 and 25 are\u8212\'3f(i) method claims for treating a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iafb0b57b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metabolic disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, such as 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic01fb554475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
type 2 diabetes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; (ii) in a patient for whom 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af0e37d475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
metformin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therapy is inappropriate because of a contraindication; (iii) by orally administering a DPP-IV inhibitor to the patient; and (iv) wherein the contraindication being, for example, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic7953171475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ica87e4b0475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal impairment
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iba86e88c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
heart failure
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, etc.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The primary difference between claim 1 and claims 24 and 25 is the recitation of a particular DPP-IV inhibitor (i.e., BI 1356) in claims 24 and 25, which is not recited in claim 1. The BI 1356 inhibitor is chemically represented as, 1-[ (4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 describes as a preferred embodiment of the DPP-IV inhibitors. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 22, ll. 40-50 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). The BI 1356 is mainly excreted via the lever and only to a minor extent via the kidney. The non-renal elimination of the BI 1356 may be of significant benefit in a patient population that has a high prevalence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39ef0e3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal insufficiency
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic4cf3424475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetic nephropathy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 23, ll. 1-10).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_13_69}{\*\bkmkend co_pp_sp_999_13_69}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*13
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court notes that claims 24 and 25, like claim 1, simply recite the act of \u8216\'3fadministering\u8217\'3f a particular DPP-IV inhibitor to a targeted patient population. Claims 24 and 25 do limit the scope of the claim to a particular DPP-IV inhibitor, BI 1356, which the disclosure of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 notes as being beneficial for patients with high prevalence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic39ef0e3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
renal insufficiency
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic63a8343475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
diabetic neuropathy
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, the Court notes that, at its core, claims 24 and 25 simply recite a single instruction of administering a drug to a targeted patient population, which is an abstract idea. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2025880702&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf23 \f2 \i1 \fs20 
{\b0 \cf23 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CyberSource Corp. v. Retail Decisions, Inc.
}
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 654 F.3d 1366, 1371 (Fed. Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[M]ethods which can be performed mentally, or which are the equivalent of human mental work, are unpatentable abstract ideas....\u8221\'3f). Lastly, like claim 1 as discussed above, the Court notes that the additional features recited in claims 24 and 25 do not add significantly more to the abstract idea of administering a DPP-IV inhibitor such that they transform the abstract idea into patent eligible subject matter. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, the Court finds that claims 24 and 25 are directed to patent ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf19 \f2 \i0 \fs20 \chcbpat24 
{\b1 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf23 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ia5121a71230011e9807fa88a5b288}{\*\bkmkend co_anchor_Ia5121a71230011e9807fa88a5b288}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, because claims 10-17 and 24-25 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 156 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are directed to an abstract idea, the Court GRANTS Defendants\rquote  motion to dismiss under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR12&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 12(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf18 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_69}{\*\bkmkend co_allCitations_69}
{\b1 \cf18 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Not Reported in Fed. Supp., 2016 WL 7177704
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012040501436_69}{\*\bkmkend co_footnote_B00012040501436_69}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012040501436_ID0ESKAE_69" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 p. 6, left column of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034571586&pubNum=0004074&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=PA&docFamilyGuid=I16a810a050a011e4b16190cc9bd4f1f4&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 156 patent
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, \u8220\'3fOther Publications\u8221\'3f section, which disclose prior publications directed towards BI 1356. For example, Thomas, L, et al: \u8220\'3fBI 1356, a novel and selective xanthine beased DPP-IV inhibitor, exhibits a superior profile when compared to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I31c9e93a4f5611dca51ecfdfa1ed2cd3&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
sitagliptin
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and vildagliptin.\u8221\'3f Diabetologoa, vol. 50, No. Suppl. 1, Sep. 2007, p. S363.
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022040501436_69}{\*\bkmkend co_footnote_B00022040501436_69}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022040501436_ID0ETHBG_69" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf23 \f3 \i1 \fs18 
{\b0 \cf23 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Enfish
}
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 822 F.3d at 1335
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (\u8220\'3fWe thus see no reason to conclude that all claims directed to improvements in computer-related technology, including those directed to software, are abstract and necessarily analyzed at the second step of 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, nor do we believe that 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 so directs. Therefore, we find it relevant to ask whether the claims are directed to an improvement to computer functionality versus being directed to an abstract idea, even at the first step of the 
}
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Alice
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 analysis\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032040501436_69}{\*\bkmkend co_footnote_B00032040501436_69}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032040501436_ID0E4OBG_69" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \i0 \fs18 \chcbpat24 
{\b1 \cf19 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf23 \f3 \i0 \fs18 \chcbpat2 
}
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. 112 (d)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
: \u8220\'3fSubject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.\u8221\'3f
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042040501436_69}{\*\bkmkend co_footnote_B00042040501436_69}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042040501436_ID0EMTBG_69" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=1015320&cite=MPEPs2111.03&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=TS&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
MPEP \u167\'3f 2111.03
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8220\'3fTransitional Phrases\u8221\'3f (\u8220\'3fThe transitional term \u8220\'3fcomprising\u8221\'3f, which is synonymous with \u8216\'3fincluding,\u8217\'3f \u8216\'3fcontaining,\u8217\'3f or \u8216\'3fcharacterized by,\u8217\'3f is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f3 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052040501436_69}{\*\bkmkend co_footnote_B00052040501436_69}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052040501436_ID0E5TBG_69" }{\fldrslt 
{\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf23 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f3 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f3 \i1 \fs18 
{\b0 \cf1 \f3 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&pubNum=1015320&cite=MPEPs2173.05(h)&originatingDoc=I33c5fa00bea611e6972aa83e6c16e5f7&refType=TS&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
MPEP \u167\'3f 2173.05(h)
}\b0 \cf23 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 \u8220\'3fAlternative Limitations\u8212\'3fMarkush Groups\u8221\'3f (A \u8216\'3fMarkush\u8217\'3f claim recites a list of alternatively useable species (\u8220\'3finternal citations omitted). A Markush claim is commonly formatted as: \u8216\'3fselected from the group consisting of A, B, and C;\u8217\'3f however, the phrase \u8216\'3fMarkush claim\u8217\'3f means any claim that recites a list of alternatively useable species regardless of format.\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f3 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f3 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf25 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf25 \f3 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf25 \f3 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf25 \f3 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf25 \f3 \ri29 \i0 \fs19 \li29 
{\b0 \cf25 \f3 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf25 \f3 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }